Alvotech signs licensing and commercialization deal with Lotus Pharmaceutical
Alvotech announces a licensing and commercialization agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and selected Asian markets.
Story updates
01:00:33 PM UTC
SquawkNews
ALVO Alvotech announces licensing and commercialization agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and selected Asian markets Alvotech - retains right to commercialize avt34 and avt87 directly in U.S. - Agreement has potential value of up to $150M in upfront and milestone payments
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.